MT-3921: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury

Grants and Contracts Details

StatusActive
Effective start/end date6/30/217/10/23

Funding

  • Mitsubishi Tanabe Pharma Development America Incorporated: $8,750.00